Ailawadhi, S., Lee, H. C., Omel, J., Toomey, K., Hardin, J. W., Gasparetto, C., … Abonour, R. (2020). Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Ailawadhi, Sikander, Hans Chulhee Lee, Jim Omel, Kathleen Toomey, James W. Hardin, Cristina Gasparetto, Sundar Jagannath, et al. “Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Ailawadhi S, Lee HC, Omel J, Toomey K, Hardin JW, Gasparetto C, et al. Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Ailawadhi, Sikander, et al. “Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Ailawadhi S, Lee HC, Omel J, Toomey K, Hardin JW, Gasparetto C, Jagannath S, Rifkin RM, Durie BG, Narang M, Terebelo HR, Wagner LI, Dhalla M, He M, Srinivasan S, Joshi PR, Robinson S, Abonour R. Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry. JOURNAL OF CLINICAL ONCOLOGY. 2020.